Johnson & Johnson (NYSE:JNJ) Shares Sold by SMART Wealth LLC

SMART Wealth LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 21.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,698 shares of the company’s stock after selling 454 shares during the quarter. SMART Wealth LLC’s holdings in Johnson & Johnson were worth $246,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of JNJ. AMF Tjanstepension AB lifted its position in shares of Johnson & Johnson by 14.2% during the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock valued at $68,985,000 after acquiring an additional 52,997 shares during the last quarter. Alpha Financial Partners LLC acquired a new position in shares of Johnson & Johnson in the 3rd quarter valued at $209,000. Wealth Group Ltd. purchased a new position in Johnson & Johnson in the 3rd quarter worth about $213,000. Rise Advisors LLC lifted its stake in Johnson & Johnson by 3.2% during the third quarter. Rise Advisors LLC now owns 3,134 shares of the company’s stock valued at $508,000 after buying an additional 96 shares in the last quarter. Finally, Willis Investment Counsel boosted its holdings in shares of Johnson & Johnson by 0.3% in the third quarter. Willis Investment Counsel now owns 308,892 shares of the company’s stock worth $50,059,000 after buying an additional 863 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Trading Up 0.7 %

Johnson & Johnson stock opened at $154.22 on Tuesday. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The company’s fifty day moving average price is $147.42 and its two-hundred day moving average price is $156.08. The company has a market capitalization of $371.31 billion, a price-to-earnings ratio of 23.19, a PEG ratio of 2.46 and a beta of 0.52. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same period in the previous year, the company earned $2.29 EPS. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.22%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Analysts Set New Price Targets

JNJ has been the subject of several research analyst reports. Raymond James reduced their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Guggenheim raised their target price on Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Morgan Stanley decreased their price objective on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $170.67.

Insiders Place Their Bets

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.